Photo by AS Photography via Pexels
Benefit from the anticipated launch of multiple late-stage R&D products.
According to GlobalData, the type 1 diabetes (T1D) market in seven major markets is expected to expand from US$220 million in 2023 to US$990 million in 2033.
This represents a CAGR of 13.3% in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. This will be driven by the expected launch of several late-stage pipeline products during the forecast period, including multiple immunomodulators.
GlobalData said the United States is the largest T1D market among the seven countries, accounting for 80.4% of global sales in 2023.
The company noted that there may still be some challenges that would slow growth. These include the high financial burden of immunomodulators, which means insurance and reimbursement restrictions will impact drug sales, and the high failure rate of clinical trials developing disease-modifying therapies in T1D.
Join the Asian Healthcare Magazine Community
Now that you're here…
….There are many ways you can work with us to promote your company and connect with your customers. Our team can help you plan and create print and digital advertising campaigns on this website and in the print magazine.
We can also organize real-life or digital events for you and source thought leadership speakers as well as industry leaders (who may be your potential partners) to attend your events. We also run a number of awards programs that give you the opportunity to be recognized for your achievements during the year, and you can join as a participant or sponsor.
Let us help you drive business development through good partnerships!
